Knockout of silent information regulator 2 (SIRT2) preserves neurological function after experimental stroke in mice

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 12, 2015, Pages 2080-2088

  Krey, Lea ^a   Lühder, Fred ^a   Kusch, Kathrin ^b   Czech Zechmeister, Bozena ^a   Könnecke, Birte ^a   Outeiro, Tiago Fleming ^a   Trendelenburg, George ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

cerebral ischemia; inflammasome; inflammation; sirtuin; stroke

Indexed keywords

CD68 ANTIGEN; MESSENGER RNA; MYELIN; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTUIN 2; SIRT2 PROTEIN, MOUSE; SIRTUIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN FUNCTION; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN REGION; BRAIN TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL LOSS; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME REGULATION; EXPERIMENTAL STROKE; GENE INACTIVATION; HEART STROKE VOLUME; MALE; MICROGLIA; MOUSE; NERVE CELL; NERVOUS SYSTEM FUNCTION; NEUTROPHIL COUNT; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; SCORING SYSTEM; ANIMAL; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CELL COUNT; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; COMPLICATION; GENE EXPRESSION; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; NERVOUS SYSTEM DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; REPERFUSION INJURY; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL COUNT; GENE EXPRESSION; INFARCTION, MIDDLE CEREBRAL ARTERY; INFLAMMATION; ISCHEMIC ATTACK, TRANSIENT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVOUS SYSTEM DISEASES; REPERFUSION INJURY; RNA, MESSENGER; SIRTUIN 2; SIRTUINS; STROKE;

EID: 84948712135     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.178     Document Type: Article

References (36)

1. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013; 14: 454-460.
2. Yildirim F, Ji S, Kronenberg G, Barco A, Olivares R, Benito E, et al. Histone acetylation and CREB binding protein are required for neuronal resistance against ischemic injury. PLoS One. 2014; 9: e95465.
3. Petegnief V, Planas AM. SIRT1 regulation modulates stroke outcome. Transl Stroke Res. 2013; 4: 663-671.
4. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab. 2011; 31: 1003-1019.
5. Hernández-Jiménez M, Hurtado O, Cuartero MI, Ballesteros I, Moraga A, Pradillo JM, et al. Silent information regulator 1 protects the brain against cerebral ischemic damage. Stroke. 2013; 44: 2333-2337.
6. Pais TF, Szego É M, Marques O, Miller-Fleming L, Antas P, Guerreiro P, et al. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J. 2013; 32: 2603-2616.
7. Ma Y, Chen H, He X, Nie H, Hong Y, Sheng C, et al. NAD+ metabolism and NAD (+)-dependent enzymes: promising therapeutic targets for neurological diseases. Curr Drug Targets. 2012; 13: 222-229.
8. Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010; 122: 2170-2182.
9. Kakefuda K, Fujita Y, Oyagi A, Hyakkoku K, Kojima T, Umemura K, et al. Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. Biochem Biophys Res Commun. 2009; 387: 784-788.
10. Newton K, Hildebrand JM, Shen Z, Rodriguez D, Alvarez-Diaz S, Petersen S, et al. Is SIRT2 required for necroptosis?. Nature. 2014; 506: E4-E6.
11. McGettrick AF, O'Neill LAJ. How metabolism generates signals during innate immunity and inflammation. J Biol Chem. 2013; 288: 22893-22898.
12. Donath MY. When metabolism met immunology. Nat Immunol. 2013; 14: 421-422.
13. Schmeisser K, Mansfeld J, Kuhlow D, Weimer S, Priebe S, Heiland I, et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat Chem Biol. 2013; 9: 693-700.
14. Nie H, Hong Y, Lu X, Zhang J, Chen H, Li Y, et al. SIRT2 mediates oxidative stressinduced apoptosis of differentiated PC12 cells. Neuroreport. 2014; 25: 838-842.
15. Ziegler G, Prinz V, Albrecht MW, Harhausen D, Khojasteh U, Nacken W, et al. Mrp-8 and -14 mediate CNS injury in focal cerebral ischemia. Biochim Biophys Acta. 2009; 1792: 1198-1204.
16. Harhausen D, Prinz V, Ziegler G, Gertz K, Endres M, Lehrach H, et al. CD93/AA4.1: a novel regulator of inflammation in murine focal cerebral ischemia. J Immunol. 2010; 184: 6407-6417.
17. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986; 17: 472-476.
18. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab. 1996; 16: 605-611.
19. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke. 1995; 26: 627-634.
20. James ML, Sullivan PM, Lascola CD, Vitek MP, Laskowitz DT. Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. Stroke. 2009; 40: 632-639.
21. Werner HB, Krämer-Albers EM, Strenzke N, Saher G, Tenzer S, Ohno-Iwashita Y, et al A critical role for the cholesterol-Associated proteolipids PLP and M6B in myelination of the central nervous system. Glia. 2013; 61: 567-586.
22. Werner HB, Kuhlmann K, Shen S, Uecker M, Schardt A, Dimova K, et al. Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci. 2007; 27: 7717-7730.
23. Southwood CM, Peppi M, Dryden S, Tainsky MA, Gow A. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem Res. 2007; 32: 187-195.
24. Harhausen D, Khojasteh U, Stahel PF, Morgan BP, Nietfeld W, Dirnagl U, et al. Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. J. Neuroinflammation. 2010; 7: 15.
25. Cohen J. Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates: Mahwah, NJ, USA, 19882.
26. Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, et al. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat Immunol. 2014; 15: 727-737.
27. Trendelenburg G. Molecular regulation of cell fate in cerebral ischemia: role of the inflammasome and connected pathways. J Cereb Blood Flow Metab. 2014; 34: 1857-1867.
28. Yang F, Wang Z, Wei X, Han H, Meng X, Zhang Y, et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J Cereb Blood Flow Metab. 2014; 34: 660-667.
29. Spires-Jones TL, Fox LM, Rozkalne A, Pitstick R, Carlson GA, Kazantsev AG. Inhibition of sirtuin 2 with sulfobenzoic acid derivative AK1 is non-Toxic and potentially neuroprotective in a mouse model of frontotemporal dementia. Front Pharmacol. 2012; 3: 42.
30. Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2012; 2: 1492-1497.
31. Li Y, Nie H, Wu D, Zhang J, Wei X, Ying W. Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-Treated microglial BV2 cells. Neurosci Lett. 2013; 544: 36-40.
32. Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, et al. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS One. 2015; 1: e0116919.
33. Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van Damme P, et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum Mol Genet. 2013; 22: 1783-1790.
34. Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS One. 2012; 7: e34805.
35. Beirowski B, Gustin J, Armour SM, Yamamoto H, Viader A, North BJ, et al. Sir-Two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci USA. 2011; 108: E952-E961.
36. Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med. 2013; 5: 344-352.